Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
Direxion Daily Energy Bull 2X Shares ETF
ERX
VanEck Semiconductor ETF
SMH
4
The Technology Select Sector SPDR® Fund
XLK
5
Invesco Solar ETF
TAN
US Stock MarketDetailed Quotes
Elicio Therapeutics (ELTX)
- 9.120
- -0.450-4.70%
Trading May 19 15:31 ET
174.07MMarket Cap-3.86P/E (TTM)
9.730High9.115Low104.10KVolume9.570Open9.570Prev Close977.81KTurnover0.78%Turnover RatioLossP/E (Static)19.09MShares14.93052wk High-121.60P/B122.23MFloat Cap5.80052wk Low--Dividend TTM13.40MShs Float263.000Historical High--Div Yield TTM6.43%Range %2.960Historical Low9.393Avg Price1Lot Size
ELTX Stock Chart
Real-Time
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
ELTX Orderflow
Unit: --
ELTX Orderflow Trend
IntradayDayWeekMonth
No Data
Elicio Therapeutics (ELTX) News
Elicio Therapeutics GAAP EPS of -$0.65 Misses by $0.18
ELICIO THERAPEUTICS ($ELTX) Releases Q1 2026 Earnings
Express News | Elicio Therapeutics Q1 EPS $(0.65) Misses $(0.47) Estimate
Elicio Therapeutics | 10-Q: Q1 2026 Earnings Report
Express News | Elicio Therapeutics Q1 Basic EPS USD -0.65
Express News | Elicio Therapeutics Q1 Net Income USD -11.823 Million
Elicio Therapeutics (ELTX) Stock Forum
$Elicio Therapeutics (ELTX.US)$
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
Wednesday, 22nd January at 7:30 am
Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and primary endpoint analysis
Phase 2 randomized study of ELI-002 fully enrolled, with formal interim analysis of disease-free survival ("DFS") expected in H1 2025; positive results could support rapid advan...
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
Wednesday, 22nd January at 7:30 am
Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and primary endpoint analysis
Phase 2 randomized study of ELI-002 fully enrolled, with formal interim analysis of disease-free survival ("DFS") expected in H1 2025; positive results could support rapid advan...
1
$Elicio Therapeutics (ELTX.US)$ Elicio Therapeutics Presents Updated Results From ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
GlobeNewswire· 12 mins ago
Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population
Strong correlation observed between mRFS and strength of T cell response
Event-driven interim analysis from randomized Phase 2 trial expected in H1 2025
GlobeNewswire· 12 mins ago
Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population
Strong correlation observed between mRFS and strength of T cell response
Event-driven interim analysis from randomized Phase 2 trial expected in H1 2025
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)